Ramucirumab 100mg<\/strong>.<\/p>\nTr\u00ecnh b\u00e0y<\/h3>\n
S\u0110K: SP3-1239-22<\/p>\n
Quy c\u00e1ch \u0111\u00f3ng g\u00f3i: H\u1ed9p 1 l\u1ecd x 10ml<\/p>\n
Xu\u1ea5t x\u1ee9:\u00a0 M\u1ef9<\/p>\n
Cyramza 100mg\/10ml \u0111i\u1ec1u tr\u1ecb ung th\u01b0 d\u1ea1 d\u00e0y, tr\u1ef1c tr\u00e0ng<\/figcaption><\/figure>\nT\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c Cyramza 100mg\/10ml<\/h2>\nC\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng<\/h3>\n
Thu\u1ed1c ch\u1ed1ng ung th\u01b0, thu\u1ed9c nh\u00f3m kh\u00e1ng th\u1ec3 \u0111\u01a1n d\u00f2ng v\u1edbi c\u01a1 ch\u1ebf ch\u00ednh nh\u1eafm v\u00e0o th\u1ee5 th\u1ec3 VEGFR-2. \u0110\u00e2y l\u00e0 ch\u1ea5t trung gian ch\u00ednh trong qu\u00e1 tr\u00ecnh h\u00ecnh th\u00e0nh m\u1ea1ch m\u00e1u, do \u0111\u00f3 s\u1ef1 \u1ee9c ch\u1ebf ng\u0103n ch\u1eb7n t\u1ea1o m\u1ea1ch m\u00e1u, gi\u1ea3m t\u0103ng sinh v\u00e0 ph\u00e1t tri\u1ec3n t\u1ebf b\u00e0o ung th\u01b0.<\/p>\n
\u0110\u1eb7c \u0111i\u1ec3m d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc<\/h3>\n